Homing of Tumor-Specific T Cells in the B16OVA/OT-I Model System - towards T Cells as Carriers of Cytotoxic Substances in Therapy of CancermelanomaimmunotherapyuveitisautoimmunityCTLA-4 antibodyCytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor exp...
Figure 2. Tumor growth curve of B16F10 and B16F10-OVA-Luc syngeneic model (n=5). Figure 3. The expression of OVA in tumors by Western Blot. 相关品系 Panc02-OVA-Luc 细胞系名称:Panc02-OVA-Luc 目录号:NMC-230050 MC38-OVA-Luc (2) ...
Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse model. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; ... C Hekim,M Ilander,M Vähä-Koskela,... - 《Euro...
Figure 2. Tumor growth curve of B16F10 and B16F10-OVA-Luc syngeneic model (n=5). Figure 3. The expression of OVA in tumors by Western Blot. 相关品系 Panc02-OVA-Luc 细胞系名称:Panc02-OVA-Luc 目录号:NMC-230050 MC38-OVA-Luc (2) ...
At a dose of 5 mg/kg/day given before tumor challenge, dasatinib therapy reduced the number of pulmonary metastases. Conversely, a higher dose (25 mg/kg/day), did not affect the number of pulmonary metastases and increased the number of extra-pulmonary metastases. Finally, immunization of ...
895: Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse modeldoi:10.1016/s0959-8049(14)50795-2M. IlanderC. HekimM. Vh-KoskelaP. SavolaS. ThtinenA. HemminkiK. Porkka...